We would love to hear your thoughts about our site and services, please take our survey here.
@Systemzero, you seem confused. ..12th Jan at 129p it's a pump n dump, 13th jan at 131p you might buy next week as it's going to finish red, 13th jan at 133p you will wait till Monday to buy in after pump n dump, 15th Jan at 131p it's bad news as update is late, 15th Jan you'll wait for lower price as target price is 150p, 16th Jan at 134.5p and delayed news = something's wrong, 16th jan at 136.5p you know think you may have missed out (although you've still got +14p till your price target), pre-open today you predict a red day today, then around 162p you decide to buy in (12p above your target sell price) and state that you know nothing about the share/company and hope it doesn't crash.
I hope nobody follows your investment strategy.
More interesting is that $1bn-$2.5bn is seen as under appreciated. That would suggest that Avacta is completely unrecognised at this point in time. Hopefully we are seen as under appreciated when the SP hits £5 - £10, then the bidding can start.
Very odd for a brand new alias being created just to warn others about what they read on the board. Why not just post using your existing alias? What's to hide?
Beware alter egos coming on this board to give you advice.
@Toukankahmoon, I think you'll find that @Pah was referring to the general period of time through which the trial has been under way with Dox being administered and not the period of time that any one patient was being dosed.
Slide/page 16 on this link will give you the details. Approx 4 cohorts to achieve MTD etc etc https://avacta.com/wp-content/uploads/2022/04/Avacta-Group-plc-Prelim-Results-2021-FINAL.pdf
The BOD are quite rightly just focused on the trial and all other projects....not the SP. The SP will take care of itself in due course, should all things go to plan. Patience as always. You never know, a licence deal may be announced sooner rather than later.
@wintzy, the trial design states that Phase 1a will have approx 4 cohorts. see page 15/16 https://avacta.com/wp-content/uploads/2022/04/Avacta-Group-plc-Prelim-Results-2021-FINAL.pdf
Very true @vegas22, but he also mentioned 60p in the other thread at 00:26...when he exposed himself (as sam smith @clonlow on Twitter). LOL.
https://twitter.com/clonlow/status/1544827764724961280?s=20&t=ogONik5qyMxihylluDLGuw
Interesting to see that Wressmycash posts on this thread and also those from MrRiipley and others which referred to his Tweets as @clonlow, have all been removed. Surely a little odd, given that there was nothing offensive therein, but simply Wressmycash making a clown of himself
it looks like that is the case @Boabyball, and it's also worth noting that these awards will also replace any previously agreed awards which were no doubt set in the past at higher rate of SP. I don't hold here but did in the last and still check in if I see any news.
@beinthelead....the change of language can only be taken as significant, otherwise why would they not have used "tumour activated" all along if the mice studies allowed them to. I'm in no doubt that changing it now has nothing to do with previous results in mice, rate or dogs.
Curious about what this bit means and whether we'll actually get a UK RNS: For investors outside the United States: Neither we nor the Registered Holders have taken any action to permit the possession or distribution of this prospectus in any jurisdiction other than the United States where action for that purpose is required. Persons outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions relating to the ADSs and ordinary shares and the distribution of this prospectus outside the United States.
Just a matter of time before they both hopefully reward patient investors.